Introduction: Perampanel is a selective, noncompetitive AMPA receptor antagonist approved as adjunctive treatment for partial seizures. To assess potential for delayed cardiac repolarization, a Phase I thorough QT study was performed, supplemented by plasma concentration-QT data modeled from 3 pooled Phase III studies. Methods: The Phase I thorough QT study (double-blind, combined fixed-sequence, parallel-group) quantified the effect of perampanel (6 mg once daily for 7 days, followed by dose escalation to a single 8-mg dose, a single 10-mg dose, then 12 mg once daily for 7 days), moxifloxacin positive control (single 400-mg dose on Day 16), and placebo on QT interval duration in healthy subjects (N = 261). Electrocardiograms were recorded at baseline, Day 7 (post 6 mg dose), and Day 16 (post 12 mg dose). Statistical comparisons were between the highest approved perampanel dose (12 mg) versus placebo, a "mid-therapeutic" dose (6 mg) versus placebo, and moxifloxacin versus placebo. Acknowledging that the Phase I thorough QT study could not incorporate a true "supratherapeutic" dose due to length of titration and tolerability concerns in healthy subjects, Phase III studies of perampanel included expanded electrocardiogram safety evaluations specifically intended to support concentration-QT response modeling. The lack of effect of perampanel on the QT interval is shown from pooled analysis of 3 double-blind, placebo-controlled, 19-week, Phase III studies with perampanel doses ≤12 mg (N = 1038, total perampanel; and N = 442, placebo) in patients with partial seizures. QT measures were corrected for heart rate using Fridericia's (QTcF; the primary endpoint) and Bazett's (QTcB) formulas. Results: In the Phase I thorough QT study, the positive control moxifloxacin caused peak time-matched, baseline-adjusted, placebo-corrected ( ) QTcF of 12.15 ms at 4 h postdose, confirming a drug effect on QTc interval and study assessment sensitivity. Mean baseline-adjusted ( ) QTcF versus nominal time curves were comparable between perampanel 12 mg and placebo, with most QTcF values being slightly negative. Healthy subjects receiving perampanel 6 and 12 mg doses for 7 days showed no evidence of effects on cardiac repolarization. Peak QTcF was 2.34 ms at 1.5 h postdose for perampanel 6 mg and 3.92 ms at 0.5 h postdose for perampanel 12 mg. At every time point, the upper 95% confidence limit of QTcF for perampanel 6 and 12 mg was <10 ms. Phase III studies revealed no clinically significant
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Introduction
The QT interval is the duration of ventricular depolarization and subsequent repolarization as measured on an electrocardiogram (ECG) from the beginning of the QRS complex to the end of the T wave (ICH Expert Working Group, 2005) . Prolongation of the QT interval has been identified as a potential risk for cardiac arrhythmias, most commonly torsade de pointes (TdP), during treatment with a variety of drugs (ICH Expert Working Group, 2005; Pollard et al., 2008; Redfern et al., 2003) . Delayed repolarization results from suppression of potassium current in cardiac tissues, the rapidly activating delayed rectifier that is mediated by the human ether-à-go-go-related gene (hERG)-encoded voltagedependent potassium channel (hERG K+ channel) (Pollard et al., 2008; Redfern et al., 2003) . Regulatory authorities require most clinical programs to examine the potential for drug-induced QT interval prolongation by conducting a thorough QT study during the course of drug development.
Perampanel is a selective, orally active, noncompetitive AMPA receptor antagonist approved in both Europe and the United States for adjunctive treatment of partial seizures with or without secondarily generalized seizures in patients 12 years of age or older with epilepsy, and in Canada for adult patients 18 years of age or; older with epilepsy (Fycompa Summary of Product Characteristcs, 2012; Fycompa Product Monogrpah, 2013; Fycompa Prescribing Information, 2014) . Perampanel has demonstrated efficacy and tolerability in partial seizures in patients ≥12 years of age in 3 multicenter, double-blind, randomized, placebocontrolled Phase III studies (French et al., , 2013 Krauss et al., 2012) .
In vitro studies indicate that perampanel blocks the hERG K+ channel in cultured cells in a dose-dependent manner at concentrations ≥10 mol/L (≥3629 ng/mL), with an estimated 50% inhibitory concentration (IC 50 ) of 15.8 mol/L (5733.82 ng/mL). No significant inhibition was observed at concentrations of ≤3 mol/L. In clinical studies, the highest plasma perampanel concentration observed in healthy subjects and patients with epilepsy was approximately 2500 ng/mL, corresponding to a free drug concentration of 0.34 mol/L. This equates to an approximate 45-fold margin between the hERG IC 50 and the plasma free drug concentration; published literature suggests that drugs with a >30-fold safety margin are typically not associated with TdP, for which QT interval prolongation is a risk (Pollard et al., 2008; Redfern et al., 2003) . Thus, therapeutic doses of perampanel were anticipated to have a low arrhythmogenic or TdP potential.
This report examines a Phase I thorough QT study of the effect of perampanel on QT interval duration and the relationship between plasma perampanel concentrations and QT interval duration in healthy subjects. The International Conference on Harmonisation (ICH) E14 Guidance, The Clinical Evaluation of QT/QTc Interval Prolongation and Proarrhythmic Potential for Non-Antiarrhythmic Drugs, provides specific recommendations concerning the design, conduct, analysis, and interpretation of clinical studies to assess the potential of a drug to delay cardiac repolarization (ICH Expert Working Group, 2005) . However, due to safety and tolerability concerns in healthy subjects, the Phase I thorough QT study could not include the recommended multiple dosing regimen of perampanel at the maximum therapeutic exposure (ICH Expert Working Group, 2005) . Acknowledging that the Phase I thorough QT study could not incorporate a true 'supratherapeutic' dose of perampanel due to the short duration of titration and tolerability concerns in healthy subjects, this report includes plasma concentration-QT data (obtained from expanded ECG safety evaluations) modeled from 3 pooled Phase III studies.
Materials and methods

Standard protocol approvals, registration, and patient consents
This analysis consists of a Phase I thorough QT study of the effect of perampanel treatment on QT interval duration (E2007-A001-013) conducted between September 2007 and March 2008 at a single site in the United States and is supplemented by plasma concentration-QT data modeled from 3 pooled Phase III studies (Study 304, NCT00699972; Study 305, NCT00699582; and Study 306, NCT00700310) conducted between April 2008 and January 2011 in more than 40 countries (French et al., , 2013 Krauss et al., 2012) . All studies were conducted in accordance with the Declaration of Helsinki, European Medicines Agency requirements, and the US Code of Federal Regulations, as appropriate. Study protocols, amendments, and informed consents were reviewed by national regulatory authorities in each country and by independent ethics committees or institutional review boards for each site. Prior to participation, all patients provided written informed consent (French et al., , 2013 Krauss et al., 2012) .
Patients
Eligible subjects for the Phase I thorough QT study included healthy male and female subjects 18-55 years of age, with a body mass index (BMI) of 18-32 kg/m 2 . Of note, subjects who had evidence of any clinically significant disease or abnormality (including hepatic impairment), or who had a clinically significant illness during the 2 months leading up to the start of study drug treatment, were excluded. The concomitant medications taken by subjects were also recorded.
Eligible patients for the three Phase III studies included individuals ≥12 years of age diagnosed with partial seizures with or without secondary generalization in accordance with the 1981 International League Against Epilepsy Classification of Epileptic Seizures (ILAE, 1981) who had experienced ≥2 antiepileptic drug (AED) failures and had ≥5 partial seizures during baseline. Patients had to have been on stable doses of up to 3 approved AEDs prior to randomization (French et al., , 2013 Krauss et al., 2012) . Concomitant medications taken by patients were recorded. Inclusion and exclusion criteria were similar for the Phase III studies and have been published previously.
Trial designs
The Phase I thorough QT study had a double-blind, activeand placebo-controlled, combined fixed-sequence, parallel-group design and included 3 treatment arms: perampanel, placebo, and moxifloxacin. Subjects were treated for 16 days. Because moxifloxacin treatment affects cardiac repolarization and it can therefore be used to demonstrate assay sensitivity, it was chosen as a positive control (Bloomfield et al., 2008) . The perampanel arm included once-daily treatment with perampanel 6 mg for 7 days (Days 1-7), followed by a dose escalation (a single 8-mg dose on Day 8 and a single 10-mg dose on Day 9), and then once-daily treatment with perampanel 12 mg for 7 days (Days 10-16); on Day 16, subjects were administered a single placebo capsule for moxifloxacin. Subjects in the placebo arm were administered the placebo tablet for perampanel on Days 1-16, followed by the placebo capsule for moxifloxacin on Day 16. Subjects in the moxifloxacin arm were administered perampanel placebo for Days 1-16, followed by a single dose of 400 mg moxifloxacin on Day 16 (Fig. 1 ). Study drug dosing was in the evening after a meal, with the exception of the on-treatment QT assessment days (Days 7 and 16), when the study drug was administered in the morning, under fasted conditions.
The Phase III studies included a 6-week baseline, prerandomization period, after which patients were randomized to once-daily double-blind treatment with perampanel or placebo for 19 weeks (6-week titration, 13-week maintenance), and then a 4-week follow-up ( Fig. 2) (French et al., , 2013 Krauss et al., 2012) .
QT assessment and pharmacokinetic sampling
To quantify the effect of perampanel on QT interval duration in the Phase I thorough QT study, a QT assessment was conducted at baseline (Day −1) and on Days 7 (post 6 mg dose) and 16 (post 12 mg dose) of treatment. The QT assessment consisted of a serial 12-lead ECG (3 standard ECGs per time point, approximately 2 min apart). To explore the relationship between plasma concentration of perampanel and QT interval duration, pharmacokinetic sampling was conducted on Days 7 and 16. ECG measurements were taken immediately prior to pharmacokinetic sampling. The baseline QT assessment was time-matched to the treatment QT assessments, and subjects received identical meals and observed identical food/fast schedules on the days of QT assessment.
In the Phase III studies, ECGs were conducted at baseline (Week −6), at Weeks 0 and 6 during the titration period, at Weeks 14 and 19 during the maintenance period, and at the end of the follow-up (Week 23). Blood samples for the measurement of plasma perampanel concentration were collected at Weeks 10, 14, and 19 during the maintenance period and at the end of the follow-up (Week 23) (Fig. 2) .
Statistical analysis
Analysis of QT interval duration in the Phase I thorough QT study employed Fridericia's method of correction for heart rate (QTcF) derived from ECGs taken at baseline (Day −1) and Days 7 and 16. Statistical comparisons were made between perampanel 12 mg and placebo, perampanel 6 mg and placebo, and moxifloxacin and placebo. Correction for heart rate was also made using Bazett's and individual correction formulas (QTcB and QTci, respectively). The mean differences at each time point in change from baseline between active treatment and placebo were compared using a repeated measures mixed effects analysis of variance (ANOVA). The mean time-matched, baseline-corrected difference is presented, along with a one-sided 95% upper confidence bound on the difference. An upper confidence limit <10 ms indicates that the active treatment did not cause a clinically relevant increase in the QT interval. In the moxifloxacin arm, assay sensitivity was tested using point estimates and confidence intervals (CIs) (two-sided 95% CI) from an ANOVA model at each time point. A significant p value with a >5 ms difference indicated assay sensitivity.
Pharmacokinetic parameters were derived from observed plasma concentrations by standard non-compartmental methods. Parameters of interest included maximum plasma concentration (C max ), time to maximum plasma concentration relative to time of dosing (t max ), and area under the concentration-time curve from predose to 12 h postdose (AUC 0-12 ).
Results
Phase I thorough QT study of the effect of perampanel treatment on QT interval duration
Subject disposition and demographics
Two hundred sixty-one subjects were randomized for treatment (perampanel, N = 111; placebo, N = 75; moxifloxacin, N = 75). Two hundred fifty subjects completed the Day 7 assessment and 233 subjects completed the Day 16 assessment. Twenty-four subjects (21.6%) in the perampanel treatment group withdrew from the study, primarily due to adverse events (AEs) (12.6%). The most commonly reported AEs were dizziness, headache, dysarthria, somnolence, ataxia, and positive rombergism. Four subjects (5.3%) in the moxifloxacin group discontinued, mainly as a result of abnormal laboratory values (2.7%). No subjects in the placebo group withdrew from the study ( Table 1 ). The use of concomitant medications was recorded in 39 subjects; 13 (12.1%) perampanel-, 12 (16.0%) placebo-, and 14 (18.7%) moxifloxacin-treated subjects received counteractive treatment for adverse events. Based on the type of medications and when they were taken, it is unlikely that the concomitant medications interfered with pharmacokinetic and pharmacodynamic assessments.
Demographics and baseline characteristics, including age, sex, race, body weight, height, and BMI, were similar across all 3 treatment arms (Table 2) .
Moxifloxacin treatment affects cardiac repolarization and demonstrates assay sensitivity
Following treatment with placebo, there was a slight decrease in QTcF at 0.5 h, which then returned to baseline and stayed at a relatively constant QTcF level of 0 ms thereafter on Days 7 and 16 (Fig. 3) . In contrast, a steep increase in QTcF from −0.75 to 7.10 ms was observed between 0.5 and 1.0 h postdose following treatment with a single administration of moxifloxacin 400 mg on Day 16 (Fig. 3B) . From 1.0 to 4.0 h the QTcF was maintained at approximately 10.00-11.50 ms, and then declined and remained at a stable 6.00-7.00 ms range between 6.0 and 12.0 h. A timematched, baseline-adjusted analysis of the mean QTcF difference ( QTcF) between moxifloxacin and placebo indicated a QTcF >5 ms at every time point between 1.0 and 12.0 h postdose; furthermore, moxifloxacin treatment resulted in a peak QTcF effect of 12.15 ms at 4 h (data not shown). Overall, QTc differences following moxifloxacin treatment compared with placebo indicate assay sensitivity (Bloomfield et al., 2008) .
Perampanel treatment does not affect cardiac repolarization
Perampanel did not have an effect on heart rate (data not shown). At the 6 mg "mid-therapeutic" and the 12 mg a Three subjects in the perampanel group withdrew consent and 1 subject failed electrocardiogram (ECG) entrance criteria prior to dosing. These 4 subjects were randomized but not dosed.
b Two subjects (n = 1 each for perampanel and moxifloxacin groups) discontinued due to abnormal laboratory values, which were also reported as adverse events. One subject in the moxifloxacin group discontinued due to abnormal laboratory value of positive pregnancy test. The 2 subjects randomized to the moxifloxacin group were taking placebo when discontinued from the study.
c Includes 1 subject who discontinued due to the ECG requirement and 1 subject who discontinued due to noncompliance.
"high-therapeutic" doses, mean (±SD) QTcF versus nominal time curves were comparable between the perampanel and placebo groups, and most QTcF values in both treatment groups were negative. Time-matched, baseline-adjusted analysis of the mean QTcF difference between perampanel treatment and placebo indicated that at both doses, perampanel treatment did not have an effect on QT interval duration in healthy subjects. The peak QTcF was 2.34 ms at 1.5 h postdose following treatment with perampanel 6 mg, and 3.92 ms at 0.5 h postdose following treatment with perampanel 12 mg (Table 3) . At every time point following treatment with perampanel 6 mg or 12 mg, the upper 95% confidence limit was <10 ms, thereby establishing a negative thorough QTc result and indicating that perampanel treatment did not cause a clinically relevant prolongation of the QT interval. Similar results were observed when using QTcB and QTci correction formulas. On Day −1 (treatment-free baseline), the number of incidents of QTcF >450 ms was comparable among the treatment groups (n = 2, placebo; n = 1, moxifloxacin; n = 1, perampanel). On Day 7, there was 1 incident of QTcF >450 ms (4-h postdose) for the perampanel treatment group and no incidents for the placebo and moxifloxacin groups. On Day 16, there was 1 incident (1-h postdose) for the perampanel treatment group, while no subject from the placebo group reported an incident. As expected from the QT prolonging nature of moxifloxacin, a total of 10 incidents from 1 h up to 4 h postdose were reported for the moxifloxacin treatment group; no incidents were reported from 6 to 12 h postdose. None of the subjects from the Phase I study had absolute QTcF >480 ms. Consistent with this analysis, no relationship was found between plasma perampanel concentration and QTcF (Fig. 4) , as indicated by the overlapping QTcF range in the perampanel 6 mg, perampanel 12 mg, and placebo groups. An investigation of time-matched, baseline-adjusted analysis of several ECG parameters (RR, PR, QRS, and QT) between perampanel 6 mg versus placebo and perampanel 12 mg versus placebo indicated some small but statistically significant differences (p < 0.05). Significant least square (LS) means differences from placebo were observed in RR (ranging from 34.2 to 41.2 for 6 mg or 12 mg); in PR (3.6 for 6 mg only); and in QT (6.2-7.4 for 6 mg or 12 mg) at various time points. However, no systematic changes in these parameters were observed and the statistical outcome was considered to reflect the large number of comparisons made and the high statistical power of the study to detect small treatment differences. Overall, perampanel treatment was not associated with clinically relevant changes in QT interval, heart rate, or other ECG parameters. Table 3 Time-matched, baseline-adjusted QTcF (ms): "mid-therapeutic" (6 mg) and "high-therapeutic" (12 mg) dose levels compared to placebo (per-protocol population a One-sided 95% confidence limit from an ANOVA model. ANOVA = analysis of variance; CL = confidence limit; LS mean = least squares mean; QTcF = time-matched, baseline-adjusted, placebo-corrected QTcF (Fridericia's correction formula).
Pooled data from Phase III studies
Subject disposition
Pooled data from the Phase III studies included 1480 patients in the safety population (perampanel, N = 1038; placebo, N = 442). All subjects were on a stable dose of at least 1 concomitant AED during treatment. The most common AEDs, i.e., those taken by at least 10% of the subjects in any group, were carbamazepine, valproic acid, lamotrigine, levetiracetam, topiramate, oxcarbazepine, clobazam, and clonazepam. Concomitant non-AED medications were also reported and were similar between perampanel and placebo-treated subjects (63.2% versus 69.2%, respectively). The Figure 4 . Perampanel plasma concentrations versus QTcF from the Phase I thorough QT study in healthy subjects. msec = milliseconds; QTcF = Fridericia's method of correction for heart rate.
Table 4
Summary of abnormal QTc results during treatment in the pooled Phase III studies (safety analysis set).
Parameter
Placebo Subjects are counted in each applicable category. Percentages are based on the number of subjects in the safety analysis set per treatment group with data during the treatment period. a Subjects treated during the double-blind study. b QTc value >450 ms recorded at only one of the scheduled visits, except for 2 subjects (8 mg perampanel) with more than one QTcB value >450 ms. QTc = QT interval corrected for heart rate; QTcB = Bazett's correction formula; QTcF = Fridericia's correction formula. most commonly taken concomitant non-AEDs were paracetamol, ibuprofen, and lorazepam (used for any indication).
ECG evaluations revealed no clinically significant results
Pooled data analysis (Table 4 ) indicated that no subject had a maximum QTcB or QTcF value >500 ms, and the percentages of subjects with values >450 ms were similar between perampanel and placebo treatment groups for QTcB (1.3% and 1.4%, respectively) and for QTcF (0.8% and 0.5%, respectively). The percentages of subjects with changes from baseline of >60 ms were low and were comparable between perampanel and placebo treatment groups for QTcB (0.2% and 0.2%, respectively) and for QTcF (0.2% and 0.5%, respectively). There was no dose-dependent increase in the proportion of subjects with either abnormal results or large incremental changes from baseline in QTcB or QTcF. There were more females with values >450 ms for QTcB (n = 10 perampanel; n = 4 placebo) or QTcF (n = 6 perampanel; n = 2 placebo) than males [QTcB (n = 3 perampanel; n = 2 placebo) or QTcF (n = 2 perampanel; n = 0 placebo)]. Concomitant medications known to induce QT prolongation (Composite List of Drugs, 2014; Fazio et al., 2013; Letsas et al., 2011) were taken by 6 subjects with values >450 ms for QTcB (n = 1 perampanel, n = 3 placebo) or QTcF (n = 2 perampanel). No relationship was observed between plasma perampanel concentration and QT interval duration Regression analysis of individual perampanel concentrations versus corresponding QTc intervals in the Phase III studies did not indicate a clinically important relationship between plasma perampanel concentration and QT interval duration (Fig. 5) , with plasma concentrations of perampanel ranging from 1.5 to 2519.7 ng/mL. There is no evidence of prolonged QT interval duration with perampanel treatment over a wide concentration range, higher than that observed in healthy subjects in the Phase I thorough QT study.
Discussion
The most common cause of epilepsy-related death is sudden unexpected death in epilepsy (SUDEP), accounting for 7-17% of deaths in these patients (Christidis et al., 2006; Feldman and Gidal, 2013) . Although the pathophysiology of SUDEP has not been fully elucidated, possible mechanisms include impaired cardiac repolarization and seizure-associated arrhythmias (Feldman and Gidal, 2013) . Off-target effects of certain AEDs may pose a risk for lengthening the QT interval and disrupting cardiac repolarization, particularly those that work through blocking voltage-gated ion channels (Feldman and Gidal, 2013) . However, experimental and clinical findings suggest that AEDs pose little risk of increasing QT interval prolongation (Feldman and Gidal, 2013) . Furthermore, prolongation of the QT interval has been linked to an increased risk for cardiac arrhythmias, most commonly TdP, during treatment with a number of different drugs (ICH Expert Working Group, 2005; Pollard et al., 2008; Redfern et al., 2003) . As a result, regulatory authorities usually require a thorough QT study during the course of drug development to assess the potential for drug-induced prolongation of the QT interval.
In this report, we demonstrated that the AED perampanel does not appear to affect QT interval duration in either of the study populations examined. The results of the Phase I thorough QT study indicate that time-matched, baseline-adjusted mean QTcF differences were comparable between perampanel-and placebotreated healthy subjects at both the 6 mg "mid-therapeutic" and the 12 mg "high-therapeutic" doses. In addition, the pooled analysis of patients with partial seizures from Phase III studies showed a weak and clinically unimportant relationship between plasma perampanel concentration and QT interval duration.
The ICH E14 Guidance states that characterization of the dose-effect and time course relationships in thorough QT/QTc studies should include "exploration of concentrations that are higher than those achieved following anticipated therapeutic doses." Furthermore, the guidance also states that "the drug should be tested at substantial multiples of the anticipated maximum therapeutic exposure" (ICH Expert Working Group, 2005) . The Phase I thorough QT study did not include a perampanel dose higher than the maximum recommended daily dose of 12 mg (Fycompa Prescribing Information, 2014) . The rationale for not performing studies of perampanel at doses higher than 12 mg/day is threefold. In studies of perampanel treatment, the frequency and severity of drugrelated AEs, dose reductions, and discontinuations at multiple doses of 12 mg/day have indicated that this dose is at or near the maximum tolerated dose (MTD) in healthy subjects. Furthermore, alternate study designs that include the recommended dose titration schedule for perampanel (initiate treatment at 2 mg/day, with dose increases no more frequently than weekly at increments of 2 mg) (Fycompa Prescribing Information 2014) were considered prohibitively impractical to utilize in a thorough QT study due to the required length of time needed to obtain target exposures. Finally, studies have consistently shown a lack of effect of perampanel treatment on QT interval duration. This threefold rationale provides support for the adequacy of the Phase I thorough QT study design with regard to the recommended guidelines. A potential limitation of the Phase I study is the perampanel exposure at steady state being substantially higher than after a single dose; thus a 7-day repeated dosing design was used to achieve the clinically relevant "Therapeutic" and "Supratherapeutic" exposures without leading to unnecessarily long exposure of perampanel in healthy subjects. Furthermore, the dosing regimen was intended to achieve target plasma concentrations rather than steady state. The purpose of including expanded ECG assessments in the Phase III studies was to "bridge" the concentration-QT response determined in healthy subjects with the concentration-QT response seen in patients with partial seizures. The pooled analysis of Phase III concentration-QT response data shows no significant effect of perampanel. In addition to the clinical findings, nonclinical data including an hERG assay, cardiovascular safety studies in dogs, and QT/QTc intervals after repeated dosing for 39 weeks in cynomolgus monkeys did not reveal any effects of perampanel.
Conclusions
In a Phase I thorough QT study conducted in healthy subjects, cardiac repolarization and other ECG parameters were not affected by a 7-day administration of a 6 mg "mid-therapeutic" or a 12 mg "high-therapeutic" dose of perampanel. In support of these data, in a population analysis of patients with partial seizures treated with up to 12 mg perampanel in Phase III studies, no clinically important trends in QT interval data were noted. A relationship between plasma perampanel concentration and QT interval duration was not observed in healthy volunteers or in subjects from the pooled Phase III double-blind studies. Taken together, the results show that perampanel (12 mg) does not prolong the QT interval to any clinically relevant extent and routine monitoring for cardiac parameters is not required for patients taking perampanel as prescribed (Fycompa Prescribing Information, 2014) . 
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